AccuMetab™ Human CYP2C9 Enzyme, Catalytically Active

CAT#: ITS-0426-YL3
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP2C9 for accurate Phase I drug metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
CYP2C9 is a primary hepatic Phase I enzyme that metabolizes approximately 15% of clinical drugs, specifically targeting weakly acidic compounds like NSAIDs and warfarin. Because of its narrow therapeutic index substrates, assessing CYP2C9 metabolism is vital for preventing adverse drug reactions and dose-dependent toxicities.
Key Features
Proprietary E. coli expression; High and low reductase ratio options; Targeted for NSAID and warfarin metabolism; Crucial for identifying weak acid drug-drug interactions
Applications
Drug Metabolism Studies, Reaction Phenotyping, DDI Assessment, Metabolite ID
Research Areas
ADME; Drug-Drug Interactions (DDI); Toxicology
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry